Results 91 to 100 of about 38,408 (255)

FGF-2 Induces Neuronal Death through Upregulation of System xc- [PDF]

, 2014
The cystine/glutamate antiporter (system xc-) transports cystine into cell in exchange for glutamate. Fibroblast growth factor-2 (FGF-2) upregulates system xc- selectively on astrocytes, which leads to increased cystine uptake, the substrate for ...
Albano, Rebecca, Liu, Xiaoqian, Lobner, Doug   +2 more
core   +1 more source

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.
ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim   +3 more
wiley   +1 more source

A NeuroD1 AAV‐Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease‐Like Non‐Human Primate Model

Advanced Science, Volume 13, Issue 27, 13 May 2026.
This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang, Yongpeng Qin, Bin Luo, Fan Bai, Jiangyue Liu, Long Ma, Shu He, Rongjie Chen, Yuchen Wang, Shanggong Liu, Ying Sun, Yi Chen, Shuo Zhang, Jiaqi Liang, Feng Liao, Huiyi Wei, Junjie Wei, Lu Wang, Hao Xu, Zheng Wu, Gong Chen, Wenliang Lei   +21 more
wiley   +1 more source

Pathologically Activated Neuroprotection via Uncompetitive Blockade of \u3cem\u3eN\u3c/em\u3e-Methyl-d-aspartate Receptors with Fast Off-rate by Novel Multifunctional Dimer Bis(propyl)-cognitin [PDF]

, 2010
Uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists with fast off-rate (UFO) may represent promising drug candidates for various neurodegenerative disorders.
Fu, Hongjun, Han, Yifan, Huang, Pingbo, Li, Chaoying, Li, Fushun, Li, Wenming, Luo, Jialie, Ma, Dik-Lung, Pang, Yuanping, Peoples, Robert W., Tang, Jing, Wang, Qinwen, Xia, Jun, Zhao, Yuming   +13 more
core   +1 more source

Value‐based prices of emerging disease‐modifying therapies for Alzheimer's disease in 174 countries: a cost‐effectiveness and threshold analysis

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Countries have varying, limited healthcare budgets for emerging disease‐modifying therapies. Cost‐effectiveness analysis, combined with country‐level cost‐effectiveness thresholds, can be used to estimate value‐based prices (VBPs) for lecanemab and donanemab across 174 countries.
Men Thi Hoang, James G. Kahn, Sanjib Saha, Dominic Trépel   +3 more
wiley   +1 more source

Daily Oral Memantine Attenuated the Severity of Borderline Personality Disorder Symptoms: A Double-Blind Placebo-Controlled, Randomized Clinical Trial [PDF]

, 2023
Homa Mohammadsadeghi, Maryam Soleimannejad, Samira Ramazi, Mohammadreza Shalbafan, Mehrdad Eftekhar Ardebili, Gelareh Vahabzadeh, Nooshin Ahmadirad, Fariba Karimzadeh   +7 more
openalex   +1 more source

Prevalence and impact of prescribing cascades in community‐dwelling adults: Longitudinal analysis of the Irish longitudinal study on ageing (TILDA)

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1500-1508, May 2026.
Prescribing cascades occur when medication is prescribed to prevent/treat the adverse effects of another medication and may be intentional/unintentional. This study examines the prevalence of nine prescribing cascades (ThinkCascades) in The Irish Longitudinal StuDy on Ageing (TILDA).
Ann Sinéad Doherty, Rose Anne Kenny, Frank Moriarty, Fiona Boland, Barbara Clyne, Tom Fahey, Denis O' Mahony, Emma Wallace   +7 more
wiley   +1 more source

Development and Validation of a Simple UV–HPLC Method to Quantify the Memantine Drug Used in Alzheimer’s Treatment

Pharmaceuticals
Memantine, a non-competitive NMDA receptor antagonist, is used to treat Alzheimer’s disease. Therefore, loading memantine in nanoparticles (NPs) could be an essential tool to improve the treatment effectiveness while reducing drug toxicity.
Débora Nunes, Tânia G. Tavares, Frenacisco Xavier Malcata, Joana A. Loureiro, Maria Carmo Pereira   +4 more
doaj   +1 more source

Behavioral assessment of antidepressant activity of Memantine - a NMDA receptor antagonist in animal models: An experimental study

National Journal of Physiology, Pharmacy and Pharmacology, 2018
Background: Around 5–10% of patients on selective serotonin reuptake inhibitors discontinue therapy because of side effects. Therefore, research for newer antidepressants with greater effectiveness has to be explored.
Harish G Bagewadi, Rajeshwari, Banderao V Patil   +2 more
doaj   +1 more source

A retrospective review of memantine use and COVID‐19‐associated mortality from a national database [PDF]

, 2020
Moon Ho Park, Do‐Young Kwon
openalex   +1 more source